In April 2018, CIP VII signed an agreement with CDC Group, the UK government’s development finance institution, to commit up to $300m to pursue secondary opportunities in India-focused private equity funds. The transaction combines CDC’s deep knowledge of the Indian market with Coller Capital’s expertise in complex investments and innovative transaction structures. In May 2018 the partnership closed on its first transaction, the $98m GP-led secondary investment in a 2008-vintage India-focused fund.
In 2018, CIP VII led the world’s largest GP-led transaction of its time: a liquidity offer made for €2.2bn to Nordic Capital investors.
In March 2018, CIP VII acquired 45 LP positions, totalling $350m, from Aberdeen Private Equity Funds Limited.
In July 2017 CIP VII invested £125m into the public to private acquisition of Shawbrook Bank by Pollen Street Capital and BC Partners.
In August 2016, CIP VII acquired a $257m portfolio of senior secured loans managed by Northport Capital. The team was spun out into CVC’s direct lending platform.
In July 2016, CIP VI and CIP VII committed $288m to a GP-led transaction: a liquidity offer made to J C Flowers investors.
In July 2015, CIP VI was the lead investor in a transaction, committing $645m, which allowed Irving Place Capital to reposition its 2006-vintage fund and establish a new investment vehicle.
In September 2014, CIP VI acquired a €175m funds & directs portfolio from a leading Italian bank, Monte dei Paschi di Siena.
In May 2014, CIP VI was a leading member of an investor group which established American Capital’s third private equity fund, that consisted of seven companies from previous funds and capital for new investments.
In December 2013, CIP VI was part of a syndicate which purchased the interests of Absa Capital Private Equity Funds I from Barclays Africa Group.
In August 2012, CIP VI agreed to fund the acquisition of a $1.9bn private equity portfolio from Lloyds Banking Group.
In December 2011, CIP VI acquired 100% of Crédit Agricole Private Equity (CAPE) and the majority of the underlying funds that CAPE manages.
In July 2010, CIP VI, formed a joint venture with Lloyds Banking Group to acquire a £480m portfolio from the bank.
In September 2009, CIP V, purchased the majority of 3i’s remaining venture portfolio of technology and life sciences companies alongside HarbourVest Partners and DFJ Esprit. Coller Capital won Venture Capital Deal of the Year, 2009 for this transaction.
In February 2009, CIP V participated in an innovative rights issue and share placement by SVG Capital plc – the major investor in Permira buyout funds. Through this rights issue, CIP V acquired a 20% stake in the business.
In November 2008, the first commitment was made to a series of CLO porfolios across CIP V, CIP VI and CIP VII funds.
In March 2007, CIP V established a $1bn joint venture with Shell to develop a portfolio of 34 investments. The joint venture structure enables Shell to maintain its existing strategic links with the portfolio companies, whilst benefiting from Coller Capital’s expertise and resources as a financial investor.
In December 2006, CIP IV formed a €193m joint venture with ABN AMRO Capital. Forbion Capital Partners span out of the bank to manage the portfolio of 26 life science companies.